A Study of Tucatinib (ONT-380) Combined With Capecitabine and/or Trastuzumab in Patients With HER2+ Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2 Positive Metastatic Breast Cancers
Interventions: DRUG: Tucatinib|DRUG: Capecitabine|DRUG: Trastuzumab
Sponsor: Seagen Inc.